Date: April 20th, 2017

Trobalt (retigabine) discontinuation: important reminder

Dear Healthcare professional:

Trobalt (retigabine) 50 mg, 100 mg, 200 mg, 300 mg, 400 mg tablets – Global Product Discontinuation

GlaxoSmithKline (GSK) is reminding healthcare providers that Trobalt (retigabine) tablets (50 mg, 100 mg, 200 mg, 300 mg, and 400 mg) will no longer be available after June 2017. GSK intends to discontinue the product permanently. This is due to the very limited usage of the medicine and not for reasons of efficacy or safety.

Action required by healthcare providers

- All patients must be withdrawn from Trobalt by the end of June 2017. Healthcare providers are urged to safely transfer any remaining patients on Trobalt to an alternative medication where required, at the discretion of the treating physician.
- Withdrawal of a patient from Trobalt should be gradual and take place over a period of at least 3 weeks, in accordance with the prescribing information.
- From now on, healthcare providers should not begin treating any new patients with Trobalt.
- Healthcare providers are requested to remind their colleagues of these actions, particularly if they are known to be a Trobalt prescriber.

Therapeutic indication

Trobalt (retigabine) is indicated as adjunctive treatment of drug-resistant partial onset seizures with or without secondary generalisation in patients aged 18 years or older with epilepsy, where other appropriate combinations with other medicinal products have proved inadequate or have not been tolerated.

Action being taken by GlaxoSmithKline

GSK is working closely with our distributors to ensure the medicine remains available to existing patients until the end of June 2017. Any remaining Trobalt stock will be recalled from pharmacies and wholesalers thereafter.

Adverse event reporting

Adverse events should be reported. For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard. When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, treatment dates, and product brand name.

Date of Prep: Apr 17
UK/RTG/0002/17

Adverse events should also be reported to GSK on 0800 221 441 (option 3) or email to ukpharmasafety@gsk.com

Contact(s) for Further Information/Questions
Medical Information for GSK Prescription medicines: Tel: 0800 221 441 (option 2) 8:30am to 5:30pm GMT Monday to Friday. An out of hours' service is also provided for emergencies, which goes to an external provider outside of the times stated.

Yours Sincerely,



Dr. Hamzah Baig MBBS MRCP MFPM
Associate Country Medical Director UK & Ireland

Date of Prep: Apr 17
UK/RTG/0002/17